ICER has announced its intention to review mavacamten, a drug for use in hypertrophic cardiomyopathy. The Draft Scoping Document is receiving comments from the public until April 29th while a CTAF (California Technology Assessment Forum) meeting will take place in October 2021.
“The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of mavacamten (MyoKardia and Bristol-Myers Squibb) for the treatment of hypertrophic cardiomyopathy. An FDA decision on mavacamten is expected in mid to late 2021.” Read more here.
(Source: ICER, 4/8/21)